11 June 2012

National Institute for Health and Clinical Excellence

Primary Care Rheumatology Society
PO Box 42
Northallerton
North Yorkshire
DL7 8YG

Dear Sirs

Final Appraisal Determination: Belimumab for the treatment of systemic lupus erythematosus

Thank you for your email of 31 May.

Having considered that email, I agree you should be free to argue both your grounds 2.2 and 2.3 in the alternative. I note your primary point of the two will be ground 2.2. I remain of the view that both points would fall under ground 3, but with that caveat agree they should both be considered.

Yours sincerely

Chair
National Institute for Health and Clinical Excellence